The Company expects full year 2023 GAAP operating expenses of $290M to $300M, including estimated non-cash stock-based compensation expense of approximately $50M, and full year collaboration revenue of approximately $3M million related to the Sanofi (SNY) agreement. The Company expects to end 2023 with a balance of approximately $200M in cash and investments, and for the balance to enable it to fund its operating expenses and capital expenditure requirements into the second half of 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IGMS:
- IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Igm Biosciences (IGMS) Q4 Earnings Cheat Sheet
- IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
- IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
